US 10231974
Pharmaceutical composition effective in preventing the adverse effects associated with the prolonged use of dihydrofolate reductase inhibitors
granted A61KA61K31/198A61K31/4415
Quick answer
US patent 10231974 (Pharmaceutical composition effective in preventing the adverse effects associated with the prolonged use of dihydrofolate reductase inhibitors) held by Compass Therapeutics LLC expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Compass Therapeutics LLC
- Grant date
- Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K31/198, A61K31/4415, A61K31/519, A61K31/525